1. Corporate Finance

Rethinking Financial Services in Biopharma Patient Affordability Programs

Written by Posted on Less than 0 min read

Today’s guest post comes from Bob Raffo, Senior Vice President of Financial Services & Strategic Commercial Development at Cencora.

Bob discusses the challenges faced by patient affordability programs managed by third-party vendors. He explains three ways that biopharma companies can benefit by working with a financial services provider specializing in patient affordability programs.

Click here to learn about Cencora Financial Services.

Read on for Bob’s insights.

Read more »

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute, an HMP Global Company. All rights reserved. This Feed is for personal non-commercial use only.

       
View Original Article
Member since
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/
Do you like Drug Channels's articles? Follow on social!

More from Drug Channels

  1. Data & Insights

The Promise and Challenges of Workflow Integration for Biopharma-Sponsored Patient Support Programs

Today’s guest post comes from Era Prakash, Vice President of Product Management at Cencora. Era contends that workflow integration can help biopharma companies address challenges that limit provider utilization of patient support programs. She also outlines three major challenges related to the provider workflow technology market. Click here to learn more about Cencora’s Access Network […]
2 min read
0
  1. Media & Marketing

White Bagging Update 2023: Saving Money or Shifting Costs?

Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Despite the concerted efforts of insurers such as UnitedHealthcare and Elevance Health, however, buy-and-bill remains the most common channel for these products. Below, I […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, August 2024: My $0.02 on the IRA’s MFPs, UNC’s New PBM, Amazon vs. Retail, Fixing 340B, and Mark Cuban Lets Loose

Another news-laden summer is ending. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Jersey shore: Some uncomfortable realities of the Inflation Reduction Act’s (IRA’s) first set of 10 prices Amazon goes after retail pharmacies with an amusing lack of self-awareness […]
2 min read
0
  1. Channel: Drug

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. For more on acquisition cost reimbursement for pharmacies, see Sections 8.4. and 12.3.4. of our new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. Click here to see the original […]
3 min read
0
  1. Media & Marketing

Drug Channels News Roundup, February 2024: Pharmacy Shakeout Update, High Drug Prices, 340B Realities, MDs vs. Pharmacists, and Foo Fighters

February is longer than usual this year, which means that you’ll have extra time to leap into our monthly curated selection of noteworthy news. In this issue: An update on the retail pharmacy shakeout Arguing for high drug prices A leading researcher provides a 340B reality check Physicians don’t want pharmacists getting uppity Plus, Dave […]
2 min read
0
  1. Media & Marketing

How Payers Are Reacting to Insulin Price Changes

Today’s guest post comes from Nicole Mayer, Senior Analyst at MMIT. Nicole summarizes MMIT’s research on payers’ views of two crucial market changes: (1) the Inflation Reduction Act of 2022’s requirement to cap insulin prices at $35 for Medicare beneficiaries, and (2) manufacturers’ reduction in list prices for certain insulin products. She also discusses MMIT’s […]
2 min read
0
  1. Data & Insights

How Patient Engagement Can Reduce Brand Launch Risks

Today’s guest post comes from Jessica Lens, Chief Patient Experience Officer at CareMetx. Jessica discusses the challenges of patient nonadherence. She then outlines how manufacturers can build adherence into their patient services program to increase patient engagement. To learn more about enhancing patient engagement and adherence, download CareMetx’s new report: Driving Brand Success: Minimize Risk and […]
2 min read
0
  1. Trends & External Forces

Latest CMS Data Reveal the Truth About U.S. Drug Spending

The boffins at the Centers for Medicare & Medicaid Services (CMS) recently dropped the latest National Health Expenditure (NHE) data, which measures all U.S. spending on healthcare. (Links below.) As you will see, retail and mail prescription drug spending remain a consistently small share of the $4.5 trillion that we spend on U.S. healthcare. And […]
2 min read
0
  1. Media & Marketing

BIG NEWS! HMP Global Acquires Drug Channels Institute

Paula and I have some exciting news to share with you: Drug Channels Institute is joining the HMP Global family! HMP is a leading omnichannel healthcare education, events, and market insights company. It’s a great fit for DCI. Here’s the press release: HMP Global Expands Market Reach with Strategic Acquisition of Drug Channels Institute; Launches […]
2 min read
0
  1. Trends & External Forces

Drug Channels News Roundup, May 2024: CVS & Cordavis & Humira, 340Boom, AFP Slowdown, Asembia Wrap-Up, and GLP-1 Humor

Summer unofficially began over the weekend. Let’s turn up the heat with these sizzling news bites, seared to perfection on the Drug Channels grill: CVS Health’s Cordavis business seems to want quasi-regulatory oversight of Humira biosimilars 340B’s skyrocketing growth continues, but the market is changing Plans sponsors’ fading interest in alternative funding programs A post-Asembia […]
2 min read
0
  1. Data & Insights

The Pivotal Role of Technology in Delivering Effective Patient Services

Today’s guest post comes from George Moore, Chief Information Technology Officer at CareMetx. As George explains using novel survey data, manufacturers view new technologies  as crucial for patient services. He then explains how digital technology, artificial intelligence (AI), and machine learning (ML) can be used to improve patient adherence and increase hub efficiencies. To learn […]
2 min read
0
  1. Trends & External Forces

HCP Perspectives: Access Challenges in Treating Diabetes & Obesity

Today’s guest post is from Dr. Preeti Parikh, a practicing pediatrician and VP, Executive Medical Director at GoodRx. At the recent Publicis Health Media HealthFront event, Preeti hosted a dialogue on the main stage with Dr. Minisha Sood. They discussed new GoodRx research and had a candid discussion about their daily challenges in caring for […]
2 min read
0
  1. Trends & External Forces

NOW AVAILABLE: 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

I am pleased to announce Drug Channels Institute’s new 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors, available for purchase and immediate download. Download a free report overview (including key industry trends, the Table of Contents, and a List of Exhibits) Review pricing/license options and download the full 2024-25 report We’re offering special discounted […]
2 min read
0
  1. Data & Insights

White Bagging Update 2023: Saving Money or Shifting Costs? (rerun)

This week, I’m rerunning some popular posts while I prepare for Fiday’s Drug Channels Outlook 2024 live video webinar. Click here to see the original post from September 2023. Time for our annual update on the channels for provider-administered drugs. For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution […]
2 min read
0
  1. Channel: Drug

What CVS Pharmacy’s New Cost-Plus Reimbursement Approach Means for PBMs, Pharmacies, Plan Sponsors, and Prescription Prices

Is the world ready for new ways to price pharmacy and pharmacy benefit manager (PBM) services? CVS Health thinks so, as evidenced by two new initiatives that it announced yesterday. Below you’ll find details and links to source documents. I commend CVS Health for attempting to address key economic challenges facing the retail pharmacy industry […]
3 min read
0
  1. Media & Marketing

Drug Channels News Roundup, December 2023: CVS’s New GPO, Medicaid vs. PBMs, 340B in Part D, and a Rockin’ Ex-CEO

Happy New Year, everyone! It has been another wild year for our ever-evolving healthcare system. Thank you, dear readers, for welcoming Drug Channels into your inboxes, browsers, and apps. I’m proud of the diverse and thoughtful audience who follows and comments on our unique content. The Drug Channels community now encompasses 50,000+ LinkedIn followers, 25,000+ […]
2 min read
0
  1. Department: HBC

Hospitals Are Relying More on PBMs to Manage Manufacturers’ 340B Contract Pharmacy Restrictions: DCI’s 2024 Market Analysis

The 340B contract pharmacy market shows little sign of slowing down. Drug Channels Institute’s exclusive analysis of the 2024 market reveals that: About 33,000 pharmacy locations—more than half of the entire U.S. pharmacy industry—act as contract pharmacies for the hospitals and federal grantees that participate in the 340B program.  Five multi-billion-dollar, for-profit, publicly traded pharmacy […]
2 min read
0
  1. Corporate Strategy

Meet the Four Executives Headlining the Drug Channels Leadership Forum

Good news, everyone! We have secured four outstanding fireside chat participants for our inaugural Drug Channels Leadership Forum, which will be held next March in Miami. I’ll be leading one-on-one conversations with each of these executives: Steven H. Collis, Chairman, President, and CEO, Cencora, Inc. Patrick Conway, MD, MSc, CEO, Optum Rx Frank Cunningham, Group […]
2 min read
0
  1. Department: HBC

Independents Outshine PBMs in Manufacturers’ Exclusive Specialty Pharmacy Networks (rerun)

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: The 340B Drug Pricing Program: Trends, Controversies, and Outlook. Click here to see the original post from April 2024. Last week, we documented the substantial concentration of dispensing revenues for specialty drugs. See The Top 15 Specialty Pharmacies of 2023: […]
2 min read
0
  1. Media & Marketing

Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers

Today’s guest post comes from Hannah Baxter, Associate Partner at The Dedham Group; Jen Klarer, Partner, Head of Cell & Gene Therapy at The Dedham Group; and Carolyn Zele, Advisor, Solution Consulting at MMIT. The authors discuss the access barriers facing patients who need biomarker testing. They discuss five ways manufacturers can prevent these barriers […]
2 min read
0
Next